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Abstract
Purpose Early inflammation is a major factor of mucosal
reactions to radiotherapy. Pentoxifylline administration re-
sulted in a significant amelioration of radiation-induced
oral mucositis in the mouse tongue model. The underly-
ing mechanisms may be related to the immunomodulatory
properties of the drug. The present study hence focuses on
the manifestation of early inflammatory changes in mouse
tongue during daily fractionated irradiation and their poten-
tial modulation by pentoxifylline.
Materials and methods Daily fractionated irradiation with
5 fractions of 3 Gy/week (days 0–4, 7–11) was given to
the snouts of mice. Groups of 3 animals per day were eu-
thanized every second day between day 0 and 14. Pentoxi-
fylline (15 mg/kg, s. c.) was administered daily from day 5
to the day before sacrifice. The expression of the inflam-
matory proteins TNFα, NF-κB, and IL-1β were analysed.
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Results Fractionated irradiation increased the expression
of all inflammatory markers. Pentoxifylline significantly re-
duced the expression of TNFα and IL-1β, but not NF-κB.
Conclusion Early inflammation, as indicated by the ex-
pression of the inflammatory markers TNFα, NF-κB, and
IL-1β, is an essential component of early radiogenic oral
mucositis. Pentoxifylline differentially modulated the ex-
pression of different inflammatory markers. The mucopro-
tective effect of pentoxifylline does not appear to be based
on modulation of NF-κB-associated inflammation.
Keywords Fractionated irradiation · Oral mucositis · Head
and neck cancer · Radiation protection · Animal model
Frühe entzündliche Veränderungen bei
strahleninduzierter oraler Mukositis
Wirkung von Pentoxifyllin im Mausmodell
Zusammenfassung
Hintergrund und Ziel Frühe entzündliche Veränderungen
sind ein bedeutender Faktor während der Strahlenreaktion
der Schleimhaut. Die Behandlung mit Pentoxifyllin erzielte
eine signifikante Minderung strahleninduzierter oraler Mu-
kositis im Mauszungenmodel. Die zugrundeliegenden Me-
chanismen sind potenziell auf die immunomodulatorischen
Eigenschaften des Wirkstoffs zurückzuführen. Die vorlie-
genden Untersuchungen fokussieren daher auf die Mani-
festation früher entzündlicher Veränderungen in der Maus-
zunge während täglich fraktionierter Bestrahlung und deren
potenzieller Modifikation durch Pentoxifyllin.
Material und Methoden Täglich fraktionierte Bestrahlung
mit 5 Fraktionen zu 3 Gy/Woche (Tage 0–4 und 7–11) wur-
de auf die Schnauzen der Mäuse appliziert. Gruppen von
je 3 Tieren wurden in 2-tägigem Abstand eingeschläfert.
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Pentoxifyllin (15 mg/kg, s. c.) wurde täglich von Tag 5 bis
zum Tag vor der Euthanasie verabreicht. Die Expression
der Entzündungsproteine TNFα, NF-κB und IL-1β wurde
analysiert.
Ergebnisse Die fraktionierte Bestrahlung erhöhte die Ex-
pression aller entzündlicher Marker. Pentoxifyllin reduzier-
te die Expression von TNFα und IL-1β signifikant, nicht
jedoch die Expression von NF-κB.
Schlussfolgerung Frühe Entzündung, gekennzeichnet durch
die Expression der entzündlichen Marker TNFα, NF-κB
und IL-1β, ist eine essenzielle Komponente der frühen ra-
diogenen oralen Mukositis. Pentoxifyllin modulierte die
Expression jener Marker auf unterschiedliche Weise. Der
mukoprotektive Effekt von Pentoxifyllin scheint nicht auf
NF-κB-assoziierter antientzündlicher Wirkung zu beruhen.
Schlüsselwörter Fraktionierte Bestrahlung · Orale
Mukositis · Kopf-und-Hals-Tumore · Strahlenschutz ·
Tiermodell
Introduction
Oral mucositis is the most important early radiotherapy-re-
lated adverse event in head-and-neck cancer patients [1, 2].
Severe confluent epithelial radiation reactions, experienced
by the majority of patients, significantly impact the patients’
quality of life with pain, swallowing, and speaking diffi-
culties [3]. Mucositis-related hospitalization and treatment
interruptions [4] compromise the therapeutic outcome [5].
Current prophylactic and interventional strategies are purely
symptomatic [6]. Oral mucositis is associated with a pro-
nounced early inflammatory response. This offers a target
for biology-based mucositis-preventing strategies [7, 8].
Pentoxifylline (PTX), a nonspecific phosphodiesterase
inhibitor, may improve tumor oxygenation due to rheo-
logic effects, but may also ameliorate treatment-associated
normal tissue morbidity through modulation of inflamma-
tory changes [9]. When tested in a preclinical model of
radiation-induced early oral mucositis, PTX was found to
significantly reduce the incidence of mucosal ulceration in
daily fractionation studies in the established mouse tongue
model. PTX treatment yielded the most pronounced ra-
dioprotective effect, when the administration interval in-
cluded the second treatment week of fractionation. This
is the time when repopulation, the adaptive epithelial ra-
diation response [10], is already fully active. Time course
parameters of oral mucositis, i. e., latent time to the onset of
mucosal ulcerations and their respective duration, however,
were found virtually unchanged. [11].
The present study was then initiated in the same experi-
mental model in order to characterize inflammation-related
biological mechanisms of action of PTX. For this, the ex-
pression of the key inflammatory mediators interleukin-1
(IL-1-)β, tumor necrosis factor (TNF)α, and nuclear fac-
tor kappa-light-chain-enhancer of activated B cells (NF-κB)
during daily fractionated irradiation and the effect of addi-
tional PTX treatment was quantified in immunohistochemi-
cal investigations. Inflammatory changes are frequently ob-
served during the development of oral mucositis and, hence,
present an option to develop a biology-oriented treatment
strategy. NF-κB is hypothesized to be one of the key sig-
naling molecules in this aspect [8, 12] and was found up-
regulated in biopsies of oral mucosa of patients undergo-
ing myoablative therapy [8]. NF-κB is an evolutionary-con-
served signaling molecule that, as an inducible transcription
factor, regulates reactions to changes in the environment.
Although involved in the transcriptional control of various
genes, its main function is the regulation of the immune
system. NF-κB is activated upon numerous stimuli, follow-
ing either a classical, an alternative, or an atypical pathway.
Differences in the activation pathways arise from different
subsets of stimulatory molecules and, furthermore, from
subsequently recruited and differently processed intracellu-
lar binding partners. However, all pathways lead to NF-κB
activation via inducible degradation of the inhibitory protein
complex that sequesters NF-κB in the cytoplasm, followed
by NF-κB nuclear translocation and gene transcription [13].
It activates proinflammatory cytokines, chemokines, growth
and survival factors [14]. This includes TNFα, which in
turn impacts on NF-κB expression in a positive feedback
loop and presents the model stimulus for the classical NF-
κB activation pathway. TNFα mainly regulates antiapop-
totic genes and, aberrantly expressed, is involved in sev-
eral pathologic conditions, e. g., rheumatoid arthritis [15].
IL-1β presents another NF-κB-activated protein, which can
potentiate its own synthesis in autoregulatory pathways and
activates NF-κB in return [16, 17]. IL-1β is produced by
activated macrophages and is involved in various cellular




In the present experiments, mice of the inbred C3H/Neu
strain from the breeding facility of Medical Faculty Carl
Gustav Carus, Dresden, Germany were housed under spec-
ified pathogen-free conditions with controlled temperature
(21–24 °C) and humidity (30–50%). An automated light
program provided a 12/12-h light/dark rhythm, with lights
on from 06:00 am to 06:00 pm. Maximum ten animals were
kept in size 3 Macrolon® cages on saw dust bedding (Sniff
¾, Altrogge, Lage, Germany) with free access to standard
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mouse diet (Altromin 1326, Altrogge, Lage, Germany) and
filtered city tap water from standard perspex drinking bot-
tles.
Irradiation technique
The technique for irradiation of oral mucosa was described
in detail elsewhere [11, 19]. In brief, percutaneous irradia-
tion of the entire snouts of the animals was performed with
an YXLON MG325 device (Yxlon International X-ray
GmbH, Hamburg, Germany), operated at 200 kV with
a tube current of 20 mA. The animals were guided into
plastic tubes (inner diameter 28 mm). Conical holes in
a perspex block at the front end of the tubes served for
standardized positioning of the snouts. The back ends of
the tubes were closed to prevent withdrawal of the animals.
Eight animals were irradiated simultaneously. The bodies
of the mice were shielded with 6 mm of lead equivalent
MCP-96 (HEK Medizintechnik, Lübeck, Germany); the
treatment field encompassed the snouts including the en-
tire tongue. The dose homogeneity between the individual
snout irradiation fields was ±3%.
Experimental design
Daily fractionated irradiation with 5 fractions of 3 Gy/week
was applied over 2 weeks (days 0–4, 7–11). The study com-
prised three experimental arms: irradiation alone (IR), irra-
diation in combination with PTX administration (IR+PTX),
and PTX treatment alone (PTX). PTX was administered
subcutaneously at a dose of 15 mg/kg from day 5 until the
day before sacrifice; on irradiation days, the drug was given
1 h before irradiation in the IR+PTX arm. In both arms,
groups of animals (n = 3) were sacrificed every second day,
and their tongues excised at the base for further investi-
gations. Three untreated and unirradiated mice served as
a control group.
Histological preparation
The tongues were incubated in 4% paraformaldehyde for
24–48 h, cut along the median line, and subjected to rou-
tine paraffin embedding. Sections of 3 µm were mounted
on Superfrost® plus charged glass slides (Gerhard Men-
zel GmbH, Braunschweig, Germany) and dried at 37 °C
overnight. Subsequently, the sections were deparaffinized
and rehydrated through xylene and a graded alcohol series.
Heat-mediated antigen retrieval for IL-1β and NF-κB was
performed with citrate buffer, pH 6.0, boiling in a mi-
crowave set to full power for 20 min. For TNFα, epitope
unmasking was performed with EDTA buffer, pH 9.0, for
10 min, also boiling in a microwave set to full power. En-
dogenous peroxidase activity was blocked (3% hydrogen
peroxide, 10 min). The sections were then incubated with
normal goat serum (1:200), using a Vectastain® ABC Kit
(Vectastain ABC Kit, Vector Laboratories, Burlingame, CA,
USA), for 1 h at room temperature, followed by overnight
incubation at 4 °C with the primary antibodies. Anti-TNFα
(Abcam, Cambridge, MA, USA; Cat. no. 6671; rabbit poly-
clonal) was used at a concentration of 1:700, anti-IL-1β
(Novus Biologicals, Littleton, CO, USA; Cat. no. NBP1-
19775; rabbit polyclonal) at a concentration of 1:400 and
anti-NF-κB p50 (Abcam, Cambridge, MA, USA; Cat. no.
7971; rabbit polyclonal) at a concentration of 1:100. These
concentrations had been defined in previous protocol opti-
mization studies. A second section on the same slide was
incubated with the same concentration of rabbit IgG (Di-
anova GmbH, Hamburg, Germany; Cat. no. 011-000-003)
and served as a negative control. The secondary antibody
was added for 1 h at room temperature. Subsequently, the
sections were incubated with the avidin–biotin complex
solution for 1 h at room temperature. The enzyme reaction
was visualized by 3,3-diaminobenzidine (DAB) substrate
(Vectastain ABC Kit, Vector Laboratories, Burlingame,
CA, USA). Nuclear counterstaining was performed with
hematoxylin (5 min). Then, the slides were dehydrated in
a graded alcohol series, cleared in xylene and coverslipped.
Histological analysis
Analysis was performed with an Olympus light microscope
at 400× magnification. Cytoplasmic TNFα expression could
not be attributed to individual cells, hence, not the frac-
tion of expressing, positive cells, but the general staining
intensity was determined, separately for the germinal (pro-
liferative) and the functional (postmitotic) nucleated layers
of the epithelium. The signal intensity, corresponding to the
amount of secreted protein, was assessed semiquantitatively
with an arbitrary score from 0 (no signal), 1 (weak signal),
2 (intermediate signal) to 3 (strong signal). The fraction of
NF-κB p50 positive cell nuclei was evaluated separately for
the germinal and the functional epithelium. In addition, the
respective staining intensity was scored as described above
for TNFα. IL-1β was not found in the epithelium, but ex-
clusively expressed in macrophages in underlying tongue
tissues. IL-1β positive macrophages were counted within
at least 15 visual microscopic fields. The number of IL-1β
expressing macrophages in unirradiated and untreated con-
trol tongue sections was set to 100%, all further day- and
experimental arm specific mean values refer to this normal-





For statistical analysis, the SPSS statistical software (SPSS
Inc., Chicago, IL, USA) was used. Mean values and stan-
dard deviation (SD) were calculated for each animal, which
then served to calculate the mean and standard error for
each experimental group. The analysis of variance (one-
way ANOVA) was used to test for the significance of a dif-
ference between the mean values. A p-value of <0.05 was
regarded statistically significant.
Results
Representative histophotographs of immunohistochemical
staining for TNFα, NF-κB p50, and IL-1β in control spec-
imen and on days 6 and 14 are presented in Fig. 1.
TNFα
TNFα expression was minor in unirradiated and untreated
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Fig. 1 TNFα , NF-κB p50, and IL-1β expression during fractionated irradiation ± PTX and PTX alone. Representative histophotographs of lower
mouse tongue stained for TNFα, NF-κB p50 (epithelial staining), and IL-1β-positive macrophages (deeper tongue tissue, in close proximity to
blood vessels). Figures represent day 0 (unirradiated and untreated controls), day 6 and day 14 during fractionated irradiation alone (IR), with
additional PTX administration (IR+PTX), and PTX treatment alone (PTX). PTX treatment reduced the radiation-induced expression increase of
TNFα and IL-1β, but had no effect on NF-κB p50. Scale bar: 50 µm
0.6 a.u. in the germinal layer and of 0.8 a.u. in the func-
tional compartment, respectively. With the onset of daily
fractionated irradiation, as illustrated in Fig. 2, TNFα ex-
pression increased progressively. The expression maximum
was observed on day 12 (2.5 a.u.).
In the germinal epithelial layers, additional PTX treat-
ment reduced TNFα on day 0 (0.2 a.u.) and day 2 (0.2 a.u.)
relative to only irradiated specimen (0.6 a.u. and 0.8 a.u.),
respectively. Subsequently, the germinal expression in the
PTX-treated experimental arm progressed similarly to only
irradiated specimen until day 10, although the TNFα ex-
pression remained substantially lower compared to irradia-
tion alone. The expression maximum on day 12 was reduced
to 1.5 a.u. and on day 14, expression levels were found to be
significantly below those for irradiation alone (p = 0.037)
and within the normal range (0.75 a.u.) (Fig. 2a). In the
functional epithelial compartment daily fractionated irradi-
ation induced a progressive increase in TNFα expression
with a maximum on day 12 (2.1 a.u.). With additional PTX
treatment, TNFα expression developed similar to that after
irradiation alone, but was constantly substantially lower,
however, with a significant difference only being obtained
K
Strahlenther Onkol
Fig. 2 Effect of fractionated irradiation ± PTX and PTX alone on TNFα expression. TNFα expression was analyzed in the epithelium, in the
germinal (a) and functional (b) compartments, respectively. The staining signal intensity was scored semiquantitatively with an arbitrary score of
0 (no signal), 1 (weak), 2 (intermediate), or a maximum of 3 (strong). Data points represent the mean of 3 animals, error bars indicate ±1 standard
deviation (SD). The shaded areas illustrate the mean (±1 SD) from 3 control animals. The fractionation protocol is indicated on top of the abscissae.
PTX pentoxifylline, IR irradiation. *p < 0.05
Fig. 3 Effect of fractionated
irradiation ± PTX and PTX
alone on NF-κB p50 expression.
NF-κB p50 expression was an-
alyzed in the epithelium, in the
germinal (a) and functional (c)
compartments, respectively. The
staining signal intensity was
scored semiquantitatively with
an arbitrary score of 0 (no sig-
nal), 1 (weak), 2 (intermediate),
or a maximum of 3 (strong) in
both compartments as well (b
and d). Data points represent the
mean of 3 animals, error bars
indicate ±1 standard deviation
(SD). The shaded areas illustrate
the mean (±1 SD) from 3 control
animals. The fractionation pro-
tocol is indicated on top of the
abscissae. PTX pentoxifylline,
IR irradiation
at day 2 (p = 0.022) (Fig. 2b). PTX treatment alone reduced
TNFα levels to subnormal values in both the germinal and
the functional epithelial layers. Reduced epithelial TNFα
expression remained throughout the PTX treatment time
(Fig. 2a,b).
NF-κB p50
In control specimen, 47.9% of cell nuclei in the germi-
nal epithelial compartment were NF-κB p50 positive. With
daily fractionated irradiation, NF-κB p50 expression in-
creased over the normal range on day 2 (58.3%) and pro-
gressively expanded to a maximum of 83% on day 12. NF-
κB p50 staining intensity in the individual, positive cell
nuclei was not affected by daily fractionated irradiation
throughout the study period. Both the fraction of NF-κB
p50 positive cell nuclei and their respective staining inten-
sity remained unchanged by PTX treatment (Fig. 3a,b).
In the postmitotic, functional epithelial compartment,
67.2% of cell nuclei expressed NF-κB p50 in control sec-
tions. Daily fractionated irradiation progressively increased
the NF-κB p50 expression to a maximum of 88.3% nuclei
on day 10. NF-κB p50 staining intensity remained within
the control range during the study period. Additional PTX
treatment had no effect on the fraction of cell nuclei pos-
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Fig. 4 Effect of fractionated irradiation ± PTX and PTX alone on IL-1β expression in macrophages. IL-1β expression was exclusively found in
macrophages (deeper tongue tissue). The number of macrophages positive for IL-1β (a) as well as the staining signal intensity (b) was evaluated.
The staining intensity was scored semiquantitatively with an arbitrary score of 0 (no signal), 1 (weak), 2 (intermediate), or a maximum of 3 (strong).
Data points represent the mean of 3 animals, error bars indicate ±1 standard deviation (SD). The shaded areas illustrate the mean (±1 SD) from
3 control animals. The fractionation protocol is indicated on top of the abscissae. PTX pentoxifylline, IR irradiation. *p < 0.05
itively stained for NF-κB p50 or the respective staining
intensity (Fig. 3c,d).
PTX treatment alone did not substantially affect the per-
centage of NF-κB p50 positive cell nuclei or their respective
staining intensity. A minor reduction of the staining inten-
sity in only the functional layer was observed (Fig. 3a–d).
IL-1β
Daily fractionated irradiation progressively increased the
number of IL-1β positive macrophages to a maximum of
190% on day 6. Afterwards, the number of IL-1β positive
macrophages declined despite ongoing irradiation, and nor-
mal values were restored on day 12 (Fig. 4a). IL-1β staining
intensity did not change systematically throughout the study
period. Initial values of 1.8 a.u. increased to a maximum of
2.1 a.u. on days 4–8. Subsequently, the staining intensity
reentered the normal range.
Additional PTX treatment kept the number of IL-1β ex-
pressing macrophages close to or within the normal range
until day 8. The IL-1β expression maximum was delayed to
day 10 and reduced to 173%, relative to controls. However,
the only significant difference to only irradiated specimen
was found on day 6 (p = 0.022). The subsequent restora-
tion of normal values was complete on day 14. IL-1β stain-
ing intensity remained lower, compared to only irradiated
samples and within control ranges throughout the study pe-
riod (Fig. 4b). PTX treatment alone had no significant ef-
fects on either the number of IL-1β positive macrophages
or their respective staining intensity. Both parameters re-
mained largely within the control range (Fig. 4a,b).
Discussion
Virtually all head-and-neck cancer patients experience some
degree of oral mucositis during their radio(chemo)therapy,
the majority develops a severe, confluent reaction [1, 20].
Oral mucositis is associated with significant reduction of the
patients quality of life, bears the risk for systemic infections,
due to the loss of the epithelial barrier function, and for
consequential late effects in the oral cavity [21, 22]. No
biology-based treatment has so far been implemented into
clinical practice.
PTX treatment during daily fractionated irradiation re-
sulted in a significant reduction of the incidence of oral
mucositis in the mouse tongue model [11] This may be at-
tributed to a modulation of inflammatory processes which
are suggested to be a major component of (early) normal tis-
sue radiation effects [23, 24], including mucositis [25, 26].
Early inflammation is regularly observed during the clin-
ical manifestation of oral epithelial ulceration in patients.
NF-κB seems to play a key role in this aspect [8, 12].
With TNFα and IL-1β, stimuli for both the classical and
the alternative NF-κB activation pathway have been inves-
tigated this study. Furthermore, both cytokines are involved
in nociception [27]. PTX was found to ameliorate pain in
preclinical as well as clinical studies, likely due to reduced
TNFα and IL-1 release [28, 29]. This indicates that PTX
might have an antihyperalgesic effect, reducing the signifi-
cant mucositis-associated pain burden. This effect, however,
is not substantiated in the animal model used in the present
study.
Irradiation alone
In our mouse tongue model, daily fractionated irradiation
rapidly induced the expression of all inflammatory markers
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investigated. In contrast to TNFα and NF-κB expression
levels, which remained considerably high throughout the
study period, IL-1β was found to be downregulated at the
end of the first treatment week, despite ongoing irradiation.
This corresponds to the time of onset of repopulation, i. e.,
the regenerative response of oral epithelium to fractionated
irradiation [10, 30]. A potential interaction with the epithe-
lial regenerative radiation response is hence highly likely.
Irradiation with additional PTX administration
PTX exhibits potent anti-inflammatory effects [31, 32], di-
rectly inhibits TNFα, and reduces inflammation in multiple
preclinical models [33–35], chemotherapy-induced intesti-
nal (CPT-11) and oral (5-FU) mucositis [36, 37]. In com-
bination with daily fractionated irradiation, PTX had sig-
nificant effects on TNFα and IL-1β, but no effect on the
mutual downstream protein NF-κB. Being a central medi-
ator of inflammation and other biological processes, NF-
κB is regulated by multiple pathways [38]. TNFα and IL-
1 are considered major NF-κB stimuli. However, TNFα is
only one of the ligands of the tumor necrosis factor recep-
tor (TNFR) superfamily, which consists of 19 ligands and
30 receptors [39], all of which result in the activation of the
NF-κB pathway. In addition to the TNFR superfamily, Toll-
like receptor (TLR) signaling can also result in NF-κB acti-
vation. TLRs react upon stimulation by damage-associated
molecular pattern molecules (DAMP) and pathogen-associ-
ated molecular pattern molecules (PAMP) [40]. Especially
DAMPs are likely to be released after irradiation and also
PAMP signaling is likely due to changes in the host oral
microbiome [41]. Hence, it appears to be highly likely that
lacking TNFα and/or IL-1β is substituted by other stimuli.
Activation could also occur via the atypical activation path-
way. In addition to ligand-mediated activation, NF-κB can
be stimulated by reactive oxygen species, such as hydrogen
peroxide, which is abundantly produced during the radi-
olysis of intracellular water [42]. Further oxidants, such as
singlet oxygen and superoxide and reactive nitrogen species
have been shown to active NF-κB and are released by im-
mune cells during inflammation [43]. This hypothesis is
supported by the missing effect of specific TNFα inhibition
with infliximab on oral mucositis, obtained in another study
in the mouse tongue model [44].
The central role of NF-κB in the regulation of the inflam-
matory response promotes further targeting of this pathway
as a treatment strategy to reduce radio(chemo)therapy-in-
duced oral mucositis. Recently, a reduction of radiation-
induced oral mucositis by specific targeting of NF-κB was
demonstrated in the mouse tongue model [45].
PTX alone
In our study, PTX treatment alone left the expression lev-
els of all inflammatory mediatory investigated largely un-
changed and within control ranges. PTX most likely exerts
its mucositis-ameliorating activity through a mechanism
other than modulation of NF-κB associated inflammation.
Presumably, the recently demonstrated PTX-mediated
reduction of radiation-induced early epithelial hypoxia [19]
accounts for the beneficial effect. Further mechanisms, e. g.,
modulation of cell junctions or increased epithelial prolif-
eration could also contribute. Modulation of epithelial pro-
liferation by PTX is currently being investigated.
Conclusion
Based on these results, the mucositis-ameliorating effects
of PTX, observed in functional studies [11], cannot be at-
tributed to a reduction of radiation-induced NF-κB asso-
ciated inflammatory changes. Nevertheless, reduced TNFα
and IL-1β expression could alleviate mucositis-associated
pain sensation. The anti-inflammatory approach remains
a promising treatment strategy for the oral mucositis. Fur-
ther analyses of the mechanistic effects of PTX during
the development of radiation-induced oral mucositis are
required to fully elucidate its potential as mucositis-ame-
liorating treatment strategy.
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